Skip to main content
Novartis
language-selector-globe
Choose Location
  • International
  • Americas
  • Asia Pacific
  • Europe
  • Middle East & Africa
Global | English(link is external)
Novartis Foundation | English(link is external)
Argentina | Español(link is external)
Brazil | Português(link is external)
Canada | English(link is external)
Canada | Français(link is external)
Central America | Español(link is external)
Colombia | Español(link is external)
Mexico | Español(link is external)
United States | English(link is external)
Australia | English(link is external)
Bangladesh | English(link is external)
Hong Kong S.A.R. | 繁體中文(link is external)
India | English(link is external)
Indonesia | English(link is external)
Japan | 日本語(link is external)
Korea | 한국어(link is external)
Mainland China | 中文(link is external)
Malaysia | English(link is external)
Pakistan | English(link is external)
Philippines | English(link is external)
Singapore | English(link is external)
Taiwan | 繁體中文(link is external)
Thailand | ภาษาไทย(link is external)
Austria | Deutsch(link is external)
Belgium | Français(link is external)
Belgium | Nederlands(link is external)
Bulgaria | Български(link is external)
Czech Republic | Česky(link is external)
Czech Republic | English(link is external)
Denmark | Dansk(link is external)
Estonia | Eesti(link is external)
Finland | Suomalainen(link is external)
France | Français(link is external)
Germany | Deutsch(link is external)
Greece | Ελληνικά(link is external)
Hungary | Magyar(link is external)
Ireland | English(link is external)
Italy | Italiano(link is external)
Latvia | Latvian(link is external)
Lithuania | Lithuanian(link is external)
Netherlands | Nederlands(link is external)
Norway | Norsk(link is external)
Poland | Polski(link is external)
Portugal | Português(link is external)
Romania | Română(link is external)
Russia | Русский(link is external)
Serbia | Srpski(link is external)
Slovakia | Slovensky(link is external)
Slovenia | Slovenščina(link is external)
Slovenia | English(link is external)
Spain | Español(link is external)
Sweden | Svenska(link is external)
Switzerland | Deutsch(link is external)
Switzerland | Français(link is external)
Türkiye | Türkçe(link is external)
United Kingdom | English(link is external)
Egypt | English(link is external)
Israel | עברית(link is external)
Saudi Arabia | العربية(link is external)
South Africa | English(link is external)
language-selector-globe
Choose Location
International Americas Asia Pacific Europe Middle East & Africa
Argentina | Español(link is external)
Australia | English(link is external)
Austria | Deutsch(link is external)
Bangladesh | English(link is external)
Belgium | Français(link is external)
Belgium | Nederlands(link is external)
Brazil | Português(link is external)
Bulgaria | Български(link is external)
Canada | English(link is external)
Canada | Français(link is external)
Central America | Español(link is external)
Colombia | Español(link is external)
Czech Republic | Česky(link is external)
Czech Republic | English(link is external)
Denmark | Dansk(link is external)
Egypt | English(link is external)
Estonia | Eesti(link is external)
Finland | Suomalainen(link is external)
France | Français(link is external)
Germany | Deutsch(link is external)
Greece | Ελληνικά(link is external)
Hong Kong S.A.R. | 繁體中文(link is external)
Hungary | Magyar(link is external)
India | English(link is external)
Indonesia | English(link is external)
Ireland | English(link is external)
Israel | עברית(link is external)
Italy | Italiano(link is external)
Japan | 日本語(link is external)
Korea | 한국어(link is external)
Latvia | Latvian(link is external)
Lithuania | Lithuanian(link is external)
Mainland China | 中文(link is external)
Malaysia | English(link is external)
Mexico | Español(link is external)
Netherlands | Nederlands(link is external)
Norway | Norsk(link is external)
Global | English(link is external)
Novartis Foundation | English(link is external)
Pakistan | English(link is external)
Philippines | English(link is external)
Poland | Polski(link is external)
Portugal | Português(link is external)
Romania | Română(link is external)
Russia | Русский(link is external)
Saudi Arabia | العربية(link is external)
Serbia | Srpski(link is external)
Singapore | English(link is external)
Slovakia | Slovensky(link is external)
Slovenia | Slovenščina(link is external)
Slovenia | English(link is external)
South Africa | English(link is external)
Spain | Español(link is external)
Sweden | Svenska(link is external)
Switzerland | Deutsch(link is external)
Switzerland | Français(link is external)
Taiwan | 繁體中文(link is external)
Thailand | ภาษาไทย(link is external)
Türkiye | Türkçe(link is external)
United Kingdom | English(link is external)
United States | English(link is external)
    • About 

      • Board of Directors 

        • Giovanni Caforio 
        • Simon Moroney 
        • Nancy C. Andrews 
        • Ton Buechner 
        • Patrice Bula 
        • Elizabeth (Liz) Doherty 
        • Ana de Pro Gonzalo 
        • Bridgette Heller 
        • Daniel Hochstrasser 
        • Frans van Houten 
        • Elizabeth McNally 
        • John D. Young 
        • Charlotte Pamer-Wieser 
      • Executive Committee 

        • Vasant (Vas) Narasimhan 
        • Shreeram Aradhye 
        • Victor Bulto 
        • Aharon (Ronny) Gal 
        • Karen L. Hale 
        • Patrick Horber 
        • Harry Kirsch 
        • Rob Kowalski 
        • Steffen Lang 
        • Fiona Marshall 
        • Lutz Hegemann 
        • Teresa Jose 
        • Michelle Weese 
      • Products 
      • Therapeutic areas 

        • Cardiovascular, renal and metabolic 
        • Immunology 
        • Neuroscience 
        • Oncology 
      • People and culture 
      • Inclusion 

        • Promoting inclusion 
        • Building belonging 
        • Parental leave 
        • Caring for the mental health and wellbeing of our people 
      • Novartis Gene Therapies 
      • Manufacturing 
      • Quality 

        • Audit program 
        • Novartis quality management system (QMS) 
        • Product and patient safety training 
        • Regulatory inspections 
        • Product recalls 
        • Third-party suppliers 
      • Novartis and the European Union (EU) 
      • Awards and recognition 
      Mother and daughter cuddling on a bed in a kids room

      About

      Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach 296 million people worldwide.

    • Patients and caregivers 

      • Novartis commitment to patients and caregivers 
      • Diseases 
      • Patient organization funding 
      • Patients perspectives stories 
      Adult daughter talking to her senior parents on a bench in a park

      Patients and caregivers

      Information for patients and their caregivers including clinical trial recruiting, managed access programs, funding opportunities for patient organizations and side effects reporting.

    • Healthcare professionals 

      • Medical congresses and events 

        • ASCO Annual Meeting 
      • Products 
      • Novartis pipeline 
      • Managed access programs 

        • Zolgensma® Global Managed Access Program (gMAP) 
      • Novartis external funding 
      • Healthcare professional resources by country 
      • Investigator-initiated trials / studies 
      • Novartis medical information 

        • Submit medical enquiry 
      Doctor discussing illness with patient in an office

      Healthcare professionals

      Resources for physicians and other healthcare professionals including clinical trial recruiting, grant funding, congresses and country-level information.

    • Research and development 

      • Technology platforms 
      • Research disease areas 

        • Cardiovascular and metabolic disease research at Novartis 
        • DAx: exploratory disease research at Novartis 
        • Global Health disease area research at Novartis 
        • Immunology disease research at Novartis 
        • Neuroscience research at Novartis 
        • Oncology research at Novartis 
      • Novartis pipeline 
      • Research collaborations 
      • Collaborations 
      A female research scientist in a lab looking at a sample

      Research & development

      Discover how Novartis turns breakthrough science into transformative, high-value treatments.
       

    • ESG 

      • Access 

        • Creating sustainable business models 
        • Value-based pricing 
        • Sub-Saharan Africa 
        • Donations 
        • Novartis access principles 
        • Novartis oncology access 
        • Patents and licensing 
      • Environmental sustainability 

        • Climate 
        • Nature - Waste 
        • Nature - Water 
      • Ethics, risk and compliance 

        • Ethical behavior 
        • Compliance 
        • Human rights 
        • Learning and engagement 
        • Integrated risk assurance 
      • Global health 

        • Pandemic preparedness 
        • Avoidable blindness 
        • Chagas disease 
        • Leprosy 
        • Malaria 
        • Sickle cell disease (SCD) 
        • Novartis Foundation  (link is external)
      • Inclusion 
      • ESG index 
      • Reporting and transparency hub 

        • ESG rating performance 
        • Targets 
        • Patient organization funding 
        • Payments to healthcare professionals 
        • Public policy 
        • A living wage 
        • A safe workplace 
        • Animal research 
      Family and friends having a party at home

      Environmental, social and governance

      Learn about our commitments to making a positive impact on the world by providing access to innovative medicines, protecting the environment, and upholding high ethical standards. Explore the Novartis in Society Integrated Report.

    • Investors 

      • Event calendar 
      • Financial data 

        • Novartis annual results 
        • Novartis quarterly results 
        • Novartis SEC filings 
        • Product sales 
        • Fixed-income securities 
        • Expected currency impact 
      • Share data and analysis 

        • Share monitor 
        • Dividend information 
        • Share ownership 
        • Share overview 
        • Return on investment calculator 
      • Shareholder information 

        • General Meetings 
        • American Depositary Receipts (ADR) 
        • Share buyback 
        • Frequently asked questions 
      • Company overview 

        • Corporate governance 
      • Reporting and transparency hub 

        • Reporting archive 
        • ESG rating performance 
        • Publications order form 
      • ESG 
      Business woman working on her laptop in a bright atmosphere

      Investors

      Updates and resources for investors including financial information, disclosures, events, share price, ESG and reporting.

    • News 

      • Newsroom 
      • Media library  
      • Stories 
      • Subscribe 
      • Events 
      Overhead view of a meeting room with people in the foreground and screens in the background

      News

      Information for journalists including media releases, statements, stories, multimedia resources and more.

    • Careers 

      • Career search 
      • Our business functions 

        • Careers in research and development 
        • Careers in operations 
        • Careers in commercial and sales 
        • Careers in global functions 
      • Why Novartis 
      • Career hub 

        • Temporary contracts  (link is external)
      • Early careers 

        • Graduates 
        • Students 
        • US Biomedical Research internship programs 
        • Community exploration and learning lab (CELL) 
      Two business people

      Careers

      Novartis is hiring! Find open positions, learn more about our strategy and culture, and apply today.

    • Clinical trials 
    • Partnering 
    • Supplier portal 
    • Report side effects 
    • Contacts 
    Grandmother, mother and daughter smiling and laughing on a beach

    Home

    Working together, we can reimagine medicine to improve and extend people’s lives.

Global Search Navigation
  • Press releases
    • All
    • Media library
    • Site pages
    • Featured news
    • Stories
    • Clinical Trials
Hide Filters
Sort by
Sort by
Showing 113 results
  • Press release / Jun 04, 2017

    Novartis landmark study of Tafinlar® + Mekinist® demonstrates durable survival benefit at five years in patients with BRAF mutation-positive metastatic melanoma

    Study is longest follow-up to date of a BRAF and MEK inhibitor combination therapy in patients with BRAF V600-mutant metastatic melanoma[1] Study shows stable overall survival and progression-free…
  • Press release / Jun 04, 2021

    Novartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy

    Tislelizumab demonstrated a 30% reduction in the risk of death and extended median overall survival by 2.3 months compared to chemotherapy in advanced or metastatic esophageal squamous cell carcinoma…
  • Press release / Jan 19, 2024

    Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors

    In the Phase III NETTER-2 trial, Lutathera plus octreotide LAR significantly extended median PFS to 22.8 months vs. 8.5 months with high-dose octreotide LAR in patients with newly diagnosed grade 2…
  • Press release / Jun 06, 2016

    Novartis combination therapy Tafinlar® + Mekinist® demonstrates overall survival benefit at three-year follow-up in patients with advanced melanoma

    Study is longest Ph III survival follow-up to date of BRAF V600E/K mutation-positive melanoma patients who received a targeted combination therapy  Latest data show an estimated 44% of…
  • Press release / Jun 06, 2016

    Novartis pivotal data for Tafinlar® + Mekinist® demonstrated a 63 percent overall response rate in treating rare form of lung cancer

    The median Duration of Response for BRAF V600E-mutant NSCLC patients treated with Tafinlar® + Mekinist® combination therapy was 9 months   Efficacy analyses also presented for INC280 (…
  • Press release / Jun 24, 2021

    Positive survival data for Novartis investigational radioligand therapy 177Lu-PSMA-617 published in The New England Journal of Medicine

    VISION manuscript shows that 177Lu-PSMA-617 plus standard of care (SOC) significantly improved overall survival and radiographic progression-free survival for patients with metastatic castration-…
  • Press release / May 30, 2017

    Novartis next generation CAR-T cell therapy CTL119 combined with ibrutinib shows high rate of responses in CLL patients

    Eight of nine evaluable patients tested had no signs of CLL in their bone marrow at three months.CTL119 is a humanized CD19-directed CAR-T cell therapy being developed in collaboration with the…
  • Press release / Jun 02, 2023

    Novartis Kisqali® significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups

    Kisqali is the first and only CDK4/6 inhibitor to demonstrate a consistent, clinically meaningful benefit across a broad population of patients with HR+/HER2- early breast cancer, regardless of…
  • Press release / Jun 03, 2022

    New Novartis data show Piqray® effectiveness across key biomarkers in patients with HR+/HER2- metastatic breast cancer

    Biomarker analysis from Phase III SOLAR-1 study shows Piqray plus fulvestrant had clinical benefit regardless of presence of ESR1 mutations and genes implicated in CDK4/6i resistance1 Piqray plus…
  • Press release / Jun 04, 2021

    Novartis announces Tabrecta® first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC

    Tabrecta® (capmatinib) showed a median overall survival (OS) of 20.8 months in treatment-naïve patients and 13.6 months in previously-treated patients in first published mature data1,2 Tabrecta…

Pagination

  • ‹ Previous page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 12
  • › Next page

Novartis

Working together
  • Patients and caregivers
  • Healthcare professionals
  • Researchers
  • Job seekers
  • Journalists
  • Investors
Topics
  • Access
  • ESG
  • SpeakUp
Explore
  • Pipeline
  • Products
  • Clinical trials
  • Partnering
  • Events
Therapeutic areas
  • Cardiovascular, renal and metabolic
  • Immunology
  • Neuroscience
  • Oncology
  • (link is external)
  • (link is external)
  • (link is external)
  • (link is external)
  • (link is external)
Footer Bottom
© 2025 Novartis AG
  • Terms of use
  • Privacy
  • Cookie settings
  • Contacts
  • Locations
  • Site map
  • Open source
  • Web accessibility
Novartis Site Directory
This site is intended for a global audience